The Plasticity of CD4CD25FOXP3CD127 T Cells in Patients with Metastatic Renal Cell Carcinoma in the Course of Interferon-Alpha Immunotherapy.

Aims: To examine changes in subpopulation of CD4CD25Foxp3CD127 T lymphocytes (Treg) and their association with the efficiency of the IFN- therapy.

Materials And Methods: Pts with mRCC who had undergone nephrectomy were treated with IFN- at a dose of 6 × 10 U/day three times a week ( = 18). An immunophenotypic analysis of lymphocytes in peripheral blood expressing CD4, CD25, CD127, and Foxp3 antigens could be performed in 18 pts before, 2 weeks, and 2 mo after IFN- therapy and 22 normal volunteers.

Ex vivo expanded regulatory T cells CD4CD25FoxP3CD127 develop strong immunosuppressive activity in patients with remitting-relapsing multiple sclerosis.

Multiple sclerosis (MS) is an autoimmune disease characterized by defect in regulatory function of CD4CD25 T cells. We demonstrated difference in proportion of regulatory T cells CD4CD25FoxP3CD127 (Tregs) within the same patients' relapse and remission. Proportion of peripheral Tregs (pTregs) dropped almost two times in the relapse compare to remission.

Reduced number and function of CD4+CD25highFoxP3+ regulatory T cells in patients with systemic lupus erythematosus.

CD4+CD25+ regulatory T cells (Tregs) play an important role in maintaining tolerance to self-antigens controlling occurrence of autoimmune diseases. Recently, it has been shown that the transcription factor forkhead box P3 (FoxP3) is specifically expressed on CD4+CD25+ T cells. FoxP3 has been described as the master control gene for the development and function of Tregs.

Differentiation of immunostimulatory stem-cell- and monocyte-derived dendritic cells involves maturation of intracellular compartments responsible for antigen presentation and secretion.

Dendritic cells (DCs) are important for the induction of primary T-cell responses and may serve as "biologic adjuvants" in therapeutic protocols. However, given the "plasticity" of this antigen-presenting cell, it remains unclear which DC type (source, subtype, and stage of differentiation) should be applied clinically. To provide additional insight in this selection process, we have, for the first time, analyzed the in vitro differentiation of CD34(+) precursor-derived and monocyte-derived DCs for ultrastructure, phenotype, and function.